Insulet (PODD) return on equity (ROE)

Return on equity · fiscal 2025
16.3%

Insulet (PODD) earned a return on equity of 16.3% in fiscal 2025 (the year ended December 31, 2025). That is 18.2 percentage points lower than the 34.5% of fiscal 2024. Figures as of 17 Nov 2026, 22:20 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
16.3%
Change on fiscal 2024
−18.2 pts
Highest on record
34.5%fiscal 2024
Lowest on record
-215.9%fiscal 2015
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Insulet return on equity (ROE), in more detail

Across the 17 fiscal years on record (2009–2025), the highest was 34.5% in fiscal 2024 and the lowest -215.9% in fiscal 2015. The fiscal 2025 figure is higher than in 88% of the 16 earlier fiscal years on record, whose median is -26.5%.

History · 17 fiscal years

Return on equity by fiscal year

Insulet return on equity (ROE), year by year

Insulet (PODD) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202516.3% 18.2 pts down
202434.5% 6.4 pts up
202328.2% 27.2 pts up
20221.0% 2.1 pts down
20213.0% 1.9 pts up
20201.1% 14.2 pts down
201915.3% 13.7 pts up
20181.6% 18.5 pts up
2017-16.9% 28.9 pts up
2016-45.8% 170.1 pts up
2015-215.9% 154.5 pts down
2014-61.4% 25.3 pts down
2013-36.1% 81.3 pts up
2012-117.4% 62.0 pts down
2011-55.4% 36.9 pts up
2010-92.3% 24.5 pts up
2009-116.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Insulet and comparable companies
CompanyReturn on equityFiscal year
Vaxcyte PCVX-28.5%2025
Bio-Rad Laboratories BIO10.2%2025
Molina Healthcare MOH11.6%2025
Spyre Therapeutics SYRE-21.7%2025
Qiagen QGEN11.2%2025
Insulet PODD16.3%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PODD

Insulet, figure by figure

Insulet (PODD) overview: price, valuation and scorecardAll health care companies by market value

Insulet return on equity (ROE): questions and answers

What is Insulet's return on equity?

Insulet (PODD) earned a return on equity of 16.3% in fiscal 2025 (the year ended December 31, 2025). That is 18.2 percentage points lower than the 34.5% of fiscal 2024.

Is Insulet's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 88% of the 16 earlier fiscal years on record, whose median is -26.5%.

What are the highest and lowest return on equity figures on record for Insulet?

Across the 17 fiscal years on record (2009–2025), the highest was 34.5% in fiscal 2024 and the lowest -215.9% in fiscal 2015.

How is Insulet's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Insulet (PODD) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/PODD/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.